Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer.
Baka, Sofia Ashcroft, Linda Anderson, Heather Lind, Michael J Burt, Paul A Stout, Ronald Dowd, Isabel Smith, D Thatcher, Nick
Baka, Sofia
Ashcroft, Linda
Anderson, Heather
Lind, Michael J
Burt, Paul A
Stout, Ronald
Dowd, Isabel
Smith, D
Thatcher, Nick
Citations
Altmetric:
Abstract
PURPOSE: This randomized phase II study compared two treatment schedules of gemcitabine in patients with non-small-cell lung cancer (NSCLC) and impaired Karnofsky performance status (KP). Primary objectives were to record changes from baseline KP and to assess symptom palliation. Secondary objectives were overall survival, tumor response, and toxicity. PATIENTS AND METHODS: Patients with stage IIIb and IV NSCLC and KP
Description
Date
2005-04-01
Publisher
Collections
Keywords
Lung Cancer
Type
Article
Citation
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. 2005, 23 (10):2136-44 J. Clin. Oncol.